Page 26 - Read Online

Oiseth et al. Cancer immunotherapy

REFERENCES Natl Acad Sci U S A 1975;72:3666-70.
20. Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky
A, Reid TR. Going viral: a review of replication-selective oncolytic
1. Gay P, Prasad V. Few people actually benefit from “breakthrough”
cancer immunotherapy. Available from: https://www.statnews. adenoviruses. Oncotarget 2015;6:19976-89.
com/2017/03/08/immunotherapy-cancer-breakthrough/. [Last 21. Abbas AK, Lichtman AH, Pillai S. Properties and Overview of
accessed on 30 Oct 2017] Immune Responses. In: Cellular and Molecular Immunology, 9th
2. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, edition. Amsterdam: Elsevier; 2017. p. 1-11.
Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long- 22. Brodin P, Davis MM. Human immune system variation. Nat Rev
Immunol 2017;17:21-9.
term survival data from phase ii and phase iii trials of ipilimumab in 23. Loeb LA. Human cancers express mutator phenotypes: origin,
unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94.
consequences and targeting. Nat Rev Cancer 2011;11:450-7.
3. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and 24. Lindahl T, Wood RD. Quality control by DNA repair. Science
immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin 1999;286:1897-905.
Oncol 2017;14:463-82. 25. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA,
4. ASCO Daily News. Available from: https://am.asco.org/checkmate- Petrelli NJ, Anderson GR. The onset and extent of genomic instability
067-longer-follow-shows-melanoma-pfs-still-better-combo- in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A
nivolumabipilimumab. [Last accessed on 30 Oct 2017] 1999;96:15121-6.
5. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, 26. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate
McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, 27. Wang RF, Wang HY. Immune targets and neoantigens for cancer
Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab immunotherapy and precision medicine. Cell Res 2017;27:11-37.
and ipilimumab versus ipilimumab in untreated melanoma. N Engl J 28. Childs RW, Carlsten M. Therapeutic approaches to enhance natural
Med 2015;372:2006-17. killer cell cytotoxicity against cancer: the force awakens. Nat Rev
6. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Drug Discov 2015;14:487-98.
Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal 29. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB,
SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen
J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with B. How do CD4(+) T cells detect and eliminate tumor cells that either
or without pembrolizumab for advanced, non-squamous non-small- lack or express MHC class II molecules? Front Immunol 2014;5:174.
cell lung cancer: a harmacody, phase 2 cohort of the open-label 30. Burnet M. Cancer: a biological approach. III. Viruses associated with
KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508. neoplastic conditions. IV. Practical applications. Br Med J 1957;1:841-
7. Patel SH, Rimner A, Cohen RB. Combining immunotherapy and 7.
radiation therapy for small cell lung cancer and thymic tumors. Transl 31. Burnet FM. The concept of immunological surveillance. Prog Exp
Lung Cancer Res 2017;6:186-95. Tumor Res 1970;13:1-27.
8. Chida K, Nakanishi K, Shomura H, Homma S, Hattori A, Kazui K, 32. Thomas L. Discussion. In: Lawrence HS, editor. Cellular and Humoral
Taketomi A. Spontaneous regression of transverse colon cancer: a Aspects of the Hypersensitive States. New York, NY: Hoeber-Harper;
case report. Surg Case Rep 2017;3:65. 1959. p. 529-32.
9. Challis GB, Stam HJ. The spontaneous regression of cancer. A review 33. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer
of cases from 1900 to 1987. Acta Oncol 1990;29:545-50. immunoediting: from immunosurveillance to tumor escape. Nat
10. Kucerova P, Cervinkova M. Spontaneous regression of tumour and Immunol 2002;3:991-8.
the role of microbial infection - possibilities for cancer treatment. 34. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E,
Anticancer Drugs 2016;27:269-77. Shimozawa K, Nabeta Y, Kimura S, Kaya M, Nagoya S, Wada T,
11. Busch W. Aus der Sitzung der medicinischen Section vom 13 Yamashita T, Sato N. Prognostic significance of HLA class I expression
November 1867. Berlin Klin Wochenschr 1868;5:137. (in German) in osteosarcoma defined by anti-pan HLA class I monoclonal antibody,
12. Fehleisen F. Ueber die Züchtung der Erysipelkokken auf künstlichem EMR8-5. Cancer Sc 2006;97:1374-80.
Nährboden und ihre Übertragbarkeit auf den Menschen. Dtsch Med 35. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive,
Wochenschr 1882;8:553-4. (in German) and acquired resistance to cancer immunotherapy. Cell 2017;168:707-
13. Oelschlaeger TA. Bacteria as tumor therapeutics? Bioeng Bugs 23.
2010;1:146-7. 36. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen
14. Coley WB. The treatment of malignant tumors by repeated E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen
inoculations of erysipelas. With a report of ten original cases. Am J recognized by cytolytic T lymphocytes on a human melanoma.
Medical Sciences 1893;105:487-511. Science 1991;254:1643-7.
15. Coley WB. The treatment of sarcoma with the mixed toxins of 37. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.
erysipelas and Bacillus prodigiosus. Boston Med Surg J 1908;158:175- Cell 2011;144:646-74.
82. 38. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of
16. Parish CR. Cancer immunotherapy: the past, the present and the metastasis. Nat Rev Immunol 2015;15:73-86.
future. Immunol Cell Biol 2003;81:106-13. 39. McAllister SS, Weinberg RA. The tumour-induced systemic
17. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette- environment as a critical regulator of cancer progression and
Guerin in the treatment of superficial bladder tumors. J Urol metastasis. Nat Cell Biol 2014;16:717-27.
1976;116:180-3. 40. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall
18. Old LJ, Clarke DA, Benacerraf B. Effect of Bacillus Calmette-Guerin T. The urgent need to recover MHC class I in cancers for effective
infection on transplanted tumours in the mouse. Nature 1959;184:291- immunotherapy. Curr Opin Immunol 2016;39:44-51.
2. 41. Chen DS, Mellman I. Elements of cancer immunity and the cancer-
19. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An immune set point. Nature 2017;541:321-30.
endotoxin-induced serum factor that causes necrosis of tumors. Proc 42. Kager L, Pötschger U, Bielack S. Review of mifamurtide in the
258 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ October 31, 2017